A Pilot Study of 1H-Nuclear Magnetic Resonance Spectroscopic Imaging in Pediatric Patients With Primary and Metastatic Brain Tumors

Launched by NATIONAL CANCER INSTITUTE (NCI) · Nov 3, 1999

Keywords

ClinConnect Summary

Background:

* Brain tumors represent the most common solid tumor of childhood. Treatment generally includes surgery and radiation, but recurrences are frequent, particularly for high-grade lesions.
* Chemotherapy is often used in an adjuvant setting, to delay radiation therapy or for resistant disease.
* Children with brain tumors are generally followed by imaging studies, such as CT or MRI.
* Difficulty arises in trying to distinguish tumor regrowth from treatment related edema, necrosis or radiation injury.
* Proton Nuclear Magnetic Resonance Spectroscopic (NMRS) Imaging is a non-invasiv...

Gender

ALL

Eligibility criteria

• * INCLUSION CRITERIA:
• • Age less than or equal to 21 years.
• • Patients entered on this trial will also be entered on one of the Pediatric Oncology Branch's primary treatment trials (e.g., phenylacetate, phenylbutyrate, SU-101) or on the Natural History or Standard Therapy protocols. The patient's management will be determined by the primary treatment protocol.
• • Histology confirmed primary or metastatic brain tumor. Patients with a brainstem glioma are not required to have previously had a histologic diagnosis.
• • Measurable or evaluable tumor at the time of study entry.
• • Durable Power of Attorney (DPA): A DPA is required of all patients 18 - 21 years of age.
• • All patients or their legal guardians (if the patient is less than 18 years of age) must sign a document of informed consent indicating their awareness of the investigational nature and the risks of this study. When appropriate the minor patient will give verbal assent.
• EXCLUSION CRITERIA:
• • Pregnant women.
• • Any patient who is unable (either because of physical or psychological factors) to undergo imaging studies and who is not an anesthesia candidate.
• • Any patient with a metallic implant, including cardiac pacemakers, neural pacemakers, shrapnel, cochlear implants or ferrous surgical clips.
• • Any patient with a history of a severe reaction to Gadolinium or other contrast agents.

Trial Officials